marked.bio

Company

Gilead Sciences

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

sacituzumab govitecan 2

Trials

3 of 4 trials shown

  1. Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

    Active, not recruiting Phase 3 Gilead Sciences Started 2023Primary completion 2028-04 NCT05840211

    sacituzumab govitecanpaclitaxelnab-paclitaxelcapecitabine

    …or-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

  2. Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

    Recruiting Phase 1/2 Gilead Sciences Started 2026Primary completion 2028-03 NCT07736937

    TUB-040 + Carbo + BEV

    … patients who were previously documented to be HRD positive or have a germline or somatic BRCA 1/2 mutation), if PARPi therapy was locally approved at the time of testing.

    BRCA1/2 mutationOvarian Cancer

  3. Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

    Active, not recruiting Phase 2 Gilead Sciences Started 2020Primary completion 2021-08 NCT04454437

    sacituzumab govitecan

    For individuals with a documented germ-line BRCA1/BRCA2 mutation who received an approved PARP inhibitor, the PARP inhibitor can be used to meet the crite…

    BRCA1/2 mutationMetastatic Triple-negative Breast Cancer